Form 4: STERIS Executive Madsen Reports Equity Grant and Vesting

Senior VP Julia Madsen acquired 2,316 ordinary shares and 8,080 stock options as part of a compensation-related transaction.

Summary

• Julia Madsen, Senior VP and GM of Life Sciences at STERIS plc, reported the acquisition of 2,316 ordinary shares on June 2, 2026.
• The reporting person also received a grant of 8,080 employee stock options with an exercise price of $230.74.
• 127 shares were withheld to satisfy tax obligations related to the vesting of restricted shares.
• Following these transactions, the reporting person holds 12,691 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, carrying no material impact on the company's operational outlook.

Positives

• The transaction reflects standard executive compensation and equity incentive alignment.
• The reporting person maintains a significant direct ownership stake of 12,691 shares.

Negatives

• 127 shares were withheld for tax purposes, which is a standard but routine reduction in total holdings.

Risks

• The value of the granted stock options is dependent on the future market performance of STERIS plc shares exceeding the $230.74 exercise price.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a disclosure of executive equity transactions.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive compensation and does not signal a change in corporate strategy or market outlook for the medical technology sector.

Comparison to Industry Standards

• The equity grant structure is consistent with standard executive compensation packages for large-cap medical device companies.
• Tax withholding practices align with standard regulatory requirements for equity-based compensation.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard executive compensation event.

Next Steps

• Vesting of remaining restricted shares according to the schedule provided in the filing.
• Exercisability of stock options beginning June 2, 2027.

Key Dates

Keywords

STERIS, STE, Insider Trading, Form 4, Equity Compensation, Life Sciences